Her primary areas of study are Chimeric antigen receptor, Immunology, Antigen, Cytotoxic T cell and Adoptive cell transfer. Her research integrates issues of T lymphocyte, Interleukin 21, Molecular biology, Genetic enhancement and CD19 in her study of Chimeric antigen receptor. Her Immunology research is multidisciplinary, incorporating elements of Hematopoietic stem cell transplantation, Transplantation and Cancer research.
Laurence J.N. Cooper has included themes like Signal transduction, Monoclonal antibody and Virology in her Antigen study. Her Cytotoxic T cell research includes themes of T cell, CD8 and Cell biology. Within one scientific family, Laurence J.N. Cooper focuses on topics pertaining to T-cell receptor under IL-2 receptor, and may sometimes address concerns connected to Antigen presentation.
Laurence J.N. Cooper mainly focuses on Immunology, Chimeric antigen receptor, Cancer research, Antigen and Immunotherapy. Her Immunology study combines topics in areas such as Cytotoxic T cell and Transplantation. Her Cytotoxic T cell study incorporates themes from CD8 and Cell therapy.
Her study in Chimeric antigen receptor is interdisciplinary in nature, drawing from both CD28, Molecular biology, Genetic enhancement, CD19 and Cell biology. Her Antigen research incorporates elements of Virology, Monoclonal antibody, Genetically modified organism and T-cell receptor. Her Immunotherapy research integrates issues from Tumor microenvironment and Oncology.
Laurence J.N. Cooper focuses on Cancer research, Immunology, Immunotherapy, Chimeric antigen receptor and Antigen. The Cancer research study combines topics in areas such as Natural killer T cell, Cell culture, microRNA and Cytotoxicity. Her biological study deals with issues like Cytotoxic T cell, which deal with fields such as T cell.
Her Immunotherapy research incorporates themes from Interleukin 12, Genetic enhancement and B cell. Her Chimeric antigen receptor study combines topics from a wide range of disciplines, such as Transgene, Genetically modified organism, Cytokine-induced killer cell, Receptor and CD19. Her work in Antigen covers topics such as Computational biology which are related to areas like Cloning, Exome sequencing and Transcriptome.
Laurence J.N. Cooper mostly deals with Immunology, Chimeric antigen receptor, Immunotherapy, Cancer research and Antigen. Her Immunology research includes elements of Stem cell, Growth inhibition and Transplantation. Laurence J.N. Cooper has researched Chimeric antigen receptor in several fields, including Leukemia, Cytokine-induced killer cell and CD19.
As part of her studies on CD19, she often connects relevant subjects like Cytotoxic T cell. Her Cancer research study integrates concerns from other disciplines, such as Cell growth, Sleeping Beauty transposon system, Cancer immunotherapy, microRNA and T-cell receptor. The concepts of her Antigen study are interwoven with issues in Tumor necrosis factor alpha, Cancer, T cell, Metastatic breast cancer and Lymph node.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism
Hongyun Zhao;Lifeng Yang;Joelle Baddour;Abhinav Achreja.
CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells
Claudia M. Kowolik;Max S. Topp;Sergio Gonzalez;Timothy Pfeiffer.
Cancer Research (2006)
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen;Leslie Popplewell;Laurence J. Cooper;David DiGiusto.
Biology of Blood and Marrow Transplantation (2010)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman;Vladimir V. Senyukov;Srinivas S. Somanchi;Prasad V. Phatarpekar.
PLOS ONE (2012)
A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
Hiroki Torikai;Andreas Reik;Pei Qi Liu;Yuanyue Zhou.
Cord-blood engraftment with ex vivo mesenchymal-cell coculture.
Marcos J.G. de Lima;Ian McNiece;Simon N. Robinson;Mark Munsell.
The New England Journal of Medicine (2012)
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
Bipulendu Jena;Gianpietro Dotti;Laurence J. N. Cooper.
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Partow Kebriaei;Harjeet Singh;M. Helen Huls;Matthew J. Figliola.
Journal of Clinical Investigation (2016)
Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells
Kanwarpal S. Kahlon;Christine Brown;Laurence J. N. Cooper;Andrew Raubitschek.
Cancer Research (2004)
Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing
Krishna V. Komanduri;Lisa S. St. John;Marcos J.G. de Lima;John McMannis.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: